Delivered by QUT, the Bridge Program involves a consortium of pharmaceutical companies, universities and industry affiliates. Launched in 2017, the program selects 100 participants annually from across Australia to take part in face-to-face and online training in the various disciplines that contribute to the commercialisation of new medicines. The tacit industry knowledge that the Bridge Program consortium provides makes the program unique in its integration into venture capital and global pharmaceutical networks and its ability to share specific, detailed and practical know-how.
The Bridge Program was awarded industry matched funding through both MTPConnect’s Project Fund Program and now the Medical Research Future Fund’s Biomedical Translation Bridge Program to deliver an exciting education program that provides the necessary training to enable successful commercialisation of Australian pharmaceutical research. Learn more at the MTPConnect website.